---
schema_version: "secwatch.filing_event.v1"
accession: "0001000694-24-000037"
form_type: "8-K"
ticker: "NVAX"
cik: "0001000694"
company_name: "NOVAVAX INC"
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:38:05.259920+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Novavax Q2 net income $162M on $415M revenue; Sanofi partnership boosts cash to $1.1B

## Summary
- Q2 2024 total revenue $415M (vs. $424M Q2 2023); net income $162M (vs. $58M).
- Received $500M upfront + $70M equity from Sanofi; eligible for up to $700M in milestones plus royalties.
- Ended Q2 with $1.1B cash vs. $584M Dec 2023; combined R&D and SG&A down 34% YoY.
- Filed EUA amendment with FDA for 2024-2025 formula COVID-19 vaccine; BLA accepted with PDUFA April 2025.
- Targeting FY2025 combined R&D/SG&A below $500M; Phase 3 combo/flu vaccine trial starts Q4 2024.

## SEC filing metadata
- accession: 0001000694-24-000037
- form_type: 8-K
- ticker: NVAX
- cik: 0001000694
- company_name: NOVAVAX INC
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1000694/000100069424000037/0001000694-24-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1000694/000100069424000037/nvax-form8xkq2earnings2024.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001000694-24-000037
- JSON: https://secwatch.observer/filing/0001000694-24-000037.json
- Plain text: https://secwatch.observer/filing/0001000694-24-000037.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.